INTRODUCTION
In recent years, clinical sections of medical genetics and genetic counseling have been set up all over Japan. At present, there are 99 institutions, including all 80 university hospitals, with genetic counseling departments that have become members of the Japan's National Liaison Council for Clinical Sections of Medical Genetics (JNLCCSMG). The JNLCCSMG was established in 2003 for the purpose of cooperation between clinical sections of medical genetics in university hospitals and other core medical institutions (http://www.idenshiiryoubumon.org).
Predictive genetic testing is a matter of great concern for at-risk relatives of patients with late-onset hereditary neurological diseases, and is one of the most controversial topics in clinical genetics. In 2006, we performed the first nationwide survey on this issue in Japan; 1 however, little is known about the global situations and problems regarding predictive testing after 2006. Here we report the results of a follow-up nationwide survey on predictive genetic testing for late-onset hereditary neurological diseases in Japan.
MATERIALS AND METHODS
A questionnaire was sent to 89 institutional members of the JNLCCSMG (all institutional members of the JNLCCSMG on 15 August 2011). The questionnaire contained seven questions as shown in Table 1 . The chief person responsible for the genetic counseling department in each hospital was asked to fill out the questionnaire. This study was approved by the Ethical Committee of Shinshu University School of Medicine. In total, 301 clients from 257 families were reported from the 41 hospitals during the study period. The greatest interest was shown with regard to SCD (97 families, 110 clients), followed by DM1 (59 families, 69 clients), HD (46 families, 52 clients) and FAP (24 families, 35 clients). The remaining clients were interested in amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, Alzheimer's disease, facioscapulohumeral muscular dystrophy, Parkinson's disease, adrenoleukodystrophy and frontotemporal dementia and parkinsonism. The numbers of clients who actually underwent predictive genetic testing were as follows: SCD, 24 (21.8%); DM1, 27 (39.1%); HD, 14 (26.9%); FAP, 26 (74.3%); Alzheimer's disease, 1 (25%); and adrenoleukodystrophy, 1 (100%). No clients interested in amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, facioscapulohumeral muscular dystrophy, Parkinson's disease and frontotemporal dementia and parkinsonism underwent predictive genetic testing (Table 1, Q3) .
RESULTS

The
During the period of the survey, clinical geneticists were predominantly involved in genetic counseling, as they participated in X50% of the total counseling sessions in 38 of the 48 hospitals (79.2%). Neurologists participated to a certain degree in counseling sessions in 32 hospitals (66.7%). The contribution of psychiatrists was much smaller, as they participated in counseling sessions only in eight hospitals (16.7%). The participation of non-medical doctor (non-MD) staff was not common, as nurses, clinical psychologists and genetic counselors were involved in 20 (41.6%), 16 (33.3%) and 16 (33.3%) hospitals, respectively (Table 1, Q4) .
Insufficiency of genetic counseling system, especially the lack of non-MD counseling staff, was the most serious obstacle to genetic counseling and/or testing in most hospitals (Table 1, In the present study, the ratio of predictive genetic test usage was surveyed for the first time in Japan. Attitude toward predictive testing varies among counties 2-12 because of culture, nationality, religion and availability of genetic counseling and testing systems. In addition, decision-making by clients in predictive genetic testing is largely influenced by their counselors 7 . In Japan, the ratios of predictive test usage in HD (26.9%) and SCD (21.8%) were much lower than those in other countries (36-88% for HD 2-11 and 48-87% for SCD 2, 6, 11, 12 ), indicating that Japanese counselors and clients took a cautious approach toward predictive testing in untreatable neurological diseases. In addition to the Japanese culture and nationality, an insufficient psychological support system after predictive testing is considered to be an important reason for the low ratio of predictive test usage in Japan. In contrast to HD and SCD, most (74.3%) clients interested in FAP actually underwent predictive testing in Japan, suggesting that the availability of disease-modifying therapy promoted the usage of testing. [13] [14] [15] The present study showed that the respondents felt lack of non-MD counseling staff was one of the most serious issues in providing predictive testing for neurological diseases in Japan. This issue was also noted in the previous survey; 1 however, the situation has not improved since then. Institutional arrangements, such as revision of the medical insurance system regarding genetic counseling and testing, might be necessary to resolve this issue.
There are two limitations that need to be acknowledged regarding the present study. The first limitation concerns the attitude to predictive testing. Both counselor's and client's attitude to predictive testing are influenced by various factors, such as age, sex, family composition, educational background, disease type and religion. However, we did not survey such factors in this study. The second limitation is that we did not survey actual hereditary risk in each client. These issues need to be analyzed in future follow-up studies. 
